In case of emergency, or if you find this card, please contact the doctor listed below:

Doctor's Name/Clinic, Center or Hospital Name
Telephone contact:

This risk minimization document version 1 has been approved by the Saudi FDA March 2021

I pis tisk minimization document version I has been approved by the Saudi FUA March 2021



IMPORTANT MEDICAL INFORMATION INSIDE Patient Card

This document has been reviewed and approved by The Saudi Food and Drug Authority (SFDA)

This risk minimization document version 1 has been approved by the Saudi FDA March 2021

Darzalex PATIENTS: Provide this card to healthcare providers BEFORE blood transfusion and carry it for 6 months after treatment has ended. For further information please refer to the Patient Information Leaflet

Patient ID Card for Darzalex
Name:
I am taking the following medication: Daratumumab antibody product for the treatment of multiple myeloma stopped taking this medication / / / / /
Dear Healthcare Provider,
Daratumumab is associated with the risk of interference with blood typing. The Indirect Coombs test (Indirect antiglobulin test [IAT]) may show positive results in patients taking daratumumab, even in the absence of antibodies to minor blood antigens in the patient's serun which may persist for up to 6 months after the last dose. The determination of a patient's ABO and Rh blood type are not impacted. If an emergency transfusion is required, non-cross-matched, ABO/RHD-compatible RBCs can be given per local blood bank practices. For more information, please contact local medical information rervice at Janssen (Tel: +966114339133, Email: RA-MedInfoEmMarkets@ITS.JNJ.com) Additional information on interference with blood compatibility testing can be found on Darzalex Summary of Product Characteristics.
Before starting daratumumab my blood test results collected on// were: Blood type:
Other: Contact details of institution where the blood tests were performed: